Cyclin-Dependent Kinase Inhibitor Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cyclin-Dependent Kinase Inhibitor pipeline constitutes 45+ key companies continuously working towards developing 52+ Cyclin-Dependent Kinase Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Cyclin-Dependent Kinase Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Cyclin-Dependent Kinase Inhibitor Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cyclin-Dependent Kinase Inhibitor Market.

Some of the key takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Cyclin-Dependent Kinase Inhibitor treatment therapies with a considerable amount of success over the years.

*
Cyclin-Dependent Kinase Inhibitor companies working in the treatment market are Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others, are developing therapies for the Cyclin-Dependent Kinase Inhibitor treatment

*
Emerging Cyclin-Dependent Kinase Inhibitor therapies in the different phases of clinical trials are- SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others are expected to have a significant impact on the Cyclin-Dependent Kinase Inhibitor market in the coming years.

*
In April 2023, Insilico Medicine declared the successful identification of a powerful, specific, and orally absorbable small molecule CDK8 inhibitor for combating cancer. This breakthrough was achieved utilizing a structure-based generative chemistry method facilitated by the Chemistry42 multi-modal generative reinforcement learning platform. The research findings were published in the Journal of Medicinal Chemistry by the American Chemical Society, renowned for its contributions to medicinal chemistry.

*
In April 2023, Sumitomo Pharma Oncology, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to TP-1287, an experimental oral inhibitor targeting CDK9, for addressing Ewing sarcoma. TP-1287 serves as an investigative oral phosphate prodrug developed from the CDK9 inhibitor alvocidib.

*
In March 2023, Prelude Therapeutics Incorporated (Prelude) revealed a collaboration in clinical trials with BeiGene, aiming to explore their investigational CDK9 inhibitor, PRT2527, in combination with BeiGene's BTK inhibitor, zanubrutinib, for hematologic malignancies. According to the agreement, BeiGene will supply zanubrutinib to Prelude, granting Prelude complete global control over the operational, developmental, and commercial aspects associated with PRT2527.

*
In September 2022, Syros Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to SY-5609, intended for addressing pancreatic cancer. SY-5609 is an orally administered, highly selective, and potent inhibitor of cyclin-dependent kinase 7 (CDK7). Presently, it is under assessment in conjunction with chemotherapy as a potential treatment for patients confronting relapsed metastatic pancreatic cancer.

*
In September 2022, Qurient Co. Ltd. revealed its partnership with MSD (Merck & Co., Inc., Rahway, NJ., USA) through a clinical collaboration agreement concerning the examination of Q901, a specific CDK7 inhibitor, in combination with MSD's anti-PD-1 therapy KEYTRUDA Registered (pembrolizumab). As part of this agreement, Qurient will conduct a phase 1/2 study in the United States aimed at assessing the safety and effectiveness of Q901 along with KEYTRUDA for treating specific advanced solid tumors.

*
In March 2022, Kirilys Therapeutics, Inc., disclosed the closure of a seed funding round primarily overseen by Lightspeed Venture Partners. The company acquired the license for its primary compound, KRLS-017, from Ube Industries, Ltd., a leading Japanese chemical manufacturer. Additionally, Kirilys finalized a partnership pact with D2G Oncology, Inc., renowned for utilizing genetically defined animal tumor models to decipher connections between cancer genotypes and drug effectiveness. This funding round empowered Kirilys to complete all essential tasks until the IND filing of KRLS-017, including preliminary groundwork for the Phase 1 clinical development program.

Cyclin-Dependent Kinase Inhibitor Overview

Cyclin-Dependent Kinase Inhibitors (CDKIs) are a class of molecules that regulate the activity of cyclin-dependent kinases (CDKs), which are critical enzymes involved in the regulation of the cell cycle. CDKs control the progression of cells through the cell cycle by phosphorylating specific target proteins. The activity of CDKs is tightly regulated by the binding of cyclins, their regulatory subunits, and CDKIs.

Get a Free Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight [https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Cyclin-Dependent Kinase Inhibitor Drugs Under Different Phases of Clinical Development Include:

*
SY-5609: Syros Pharmaceutical

*
XL 102: Exelixis

*
PRT3645: Prelude Therapeutics

*
BLU 222: Blueprint Medicines

*
Enitociclib: Vincerx Pharma

*
SHR-6390: Jiangsu Hengrui Medicine Co.

*
Milciclib: Tiziana Life Sciences

*
XZP 3287: Xuanzhu Biopharmaceutical

*
Abemaciclib: Eli Lilly and Company

*
GB491 (lerociclib): Genor Pharma

*
Auceliciclib: Aucentra Therapeutics/University of South Australia

*
AU2-94: Aucentra Therapeutics

Cyclin-Dependent Kinase Inhibitor Route of Administration

Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical.

Cyclin-Dependent Kinase Inhibitor Molecule Type

Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics Assessment

*
Cyclin-Dependent Kinase Inhibitor Assessment by Product Type

*
Cyclin-Dependent Kinase Inhibitor By Stage and Product Type

*
Cyclin-Dependent Kinase Inhibitor Assessment by Route of Administration

*
Cyclin-Dependent Kinase Inhibitor By Stage and Route of Administration

*
Cyclin-Dependent Kinase Inhibitor Assessment by Molecule Type

*
Cyclin-Dependent Kinase Inhibitor by Stage and Molecule Type

DelveInsight's Cyclin-Dependent Kinase Inhibitor Report covers around 52+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Cyclin-Dependent Kinase Inhibitor product details are provided in the report. Download the Cyclin-Dependent Kinase Inhibitor pipeline report to learn more about the emerging Cyclin-Dependent Kinase Inhibitor therapies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Cyclin-Dependent Kinase Inhibitor Therapeutics Market include:

Key companies developing therapies for Cyclin-Dependent Kinase Inhibitor are - MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, Exelixis, -Qurient Co. Ltd., OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others.

Cyclin-Dependent Kinase Inhibitor Pipeline Analysis:

The Cyclin-Dependent Kinase Inhibitor pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.

*
Cyclin-Dependent Kinase Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor drugs and therapies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Cyclin-Dependent Kinase Inhibitor Pipeline Market Drivers

*
Rising prevalence of Cancer, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Cyclin-Dependent Kinase Inhibitor Market.

Cyclin-Dependent Kinase Inhibitor Pipeline Market Barriers

*
However, high cost associated with the treatment, side-effects associated with the Cyclin-Dependent Kinase Inhibitor immunotherapy and other factors are creating obstacles in the Cyclin-Dependent Kinase Inhibitor Market growth.

Scope of Cyclin-Dependent Kinase Inhibitor Pipeline Drug Insight

*
Coverage: Global

*
Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others

*
Key Cyclin-Dependent Kinase Inhibitor Therapies: SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others

*
Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment: Cyclin-Dependent Kinase Inhibitor current marketed and Cyclin-Dependent Kinase Inhibitor emerging therapies

*
Cyclin-Dependent Kinase Inhibitor Market Dynamics: Cyclin-Dependent Kinase Inhibitor market drivers and Cyclin-Dependent Kinase Inhibitor market barriers

Request for Sample PDF Report for Cyclin-Dependent Kinase Inhibitor Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Cyclin-Dependent Kinase Inhibitor Report Introduction

2. Cyclin-Dependent Kinase Inhibitor Executive Summary

3. Cyclin-Dependent Kinase Inhibitor Overview

4. Cyclin-Dependent Kinase Inhibitor- Analytical Perspective In-depth Commercial Assessment

5. Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics

6. Cyclin-Dependent Kinase Inhibitor Late Stage Products (Phase II/III)

7. Cyclin-Dependent Kinase Inhibitor Mid Stage Products (Phase II)

8. Cyclin-Dependent Kinase Inhibitor Early Stage Products (Phase I)

9. Cyclin-Dependent Kinase Inhibitor Preclinical Stage Products

10. Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment

11. Cyclin-Dependent Kinase Inhibitor Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cyclin-Dependent Kinase Inhibitor Key Companies

14. Cyclin-Dependent Kinase Inhibitor Key Products

15. Cyclin-Dependent Kinase Inhibitor Unmet Needs

16 . Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers

17. Cyclin-Dependent Kinase Inhibitor Future Perspectives and Conclusion

18. Cyclin-Dependent Kinase Inhibitor Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cyclindependent-kinase-inhibitor-pipeline-drugs-analysis-report-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-mei-pharma-vincerx-pharma-chordia-therapeutics-pfizer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.